Effects of a convenience drink fortified with n-3 fatty acids on the n-3 index

British Journal of Nutrition

Volumn 104, Issue 5, 2010, Pages 729-736

  Khler, Anton ^a   Bittner, Daniel ^a   Löw, Anja ^a   Von Schacky, Clemens ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Atherosclerosis; DHA; EPA; n 3 Fatty acids

Indexed keywords

DOCOSAHEXAENOIC ACID; EPOXYICOSATRIENOIC ACID; FISH OIL; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; FOOD ANALYSIS; FOOD COMPOSITION; HUMAN; INDIVIDUALITY; MAJOR CLINICAL STUDY; NUTRIENT CONCENTRATION; OUTCOME ASSESSMENT; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; BEVERAGE; BLOOD; CONTROLLED CLINICAL TRIAL; FAT INTAKE; FEMALE; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED;

ZEA MAYS;

AGED; BEVERAGES; DIETARY FATS; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; FEMALE; FISH OILS; FOOD, FORTIFIED; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED;

EID: 77956932832     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114510001054     Document Type: Article

References (39)

1. Dijkstra SC, Brouwer IA, van Rooij FJ, et al. (2009) Intake of very long chain n-3 fatty acids from fish and the incidence of heart failure: The Rotterdam Study. Eur J Heart Fail 11, 922-928.
2. Anonymous (1999) Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 354, 447-455.
3. Yokoyama M, Origasa H, Matsuzaki M, et al. (2003) Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: Rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS). Am Heart J 146, 613-620.
4. Yokoyama M, Origasa H, Matsuzaki M, et al. (2007) Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis. Lancet 369, 1090-1098.
5. Mozaffarian D & Rimm EB (2006) Fish intake, contaminants, and human health: Evaluating the risks and the benefits. J Am Med Assoc 296, 1885-1899.
6. Harris WS & von Schacky C (2004) The omega-3 index: A new risk factor for death from coronary heart disease? Prev Med 39, 212-220.
7. von Schacky C (2007) Omega-3 fatty acids and cardiovascular disease. Curr Opin Clin Nutr Metab Care 10, 129-135.
8. von Schacky C & Harris WS (2007) Cardiovascular benefits of omega-3 fatty acids. Cardiovasc Res 73, 310-315.
9. Harris WS, Sands SA, Windsor SL, et al. (2004) Omega-3 fatty acids in cardiac biopsies from heart transplantation patients: Correlation with erythrocytes and response to supplementation. Circulation 110, 1645-1649.
10. Metcalf RG, James MJ, Gibson RA, et al. (2007) Effects of fish-oil supplementation on myocardial fatty acids in humans. Am J Clin Nutr 85, 1222-1228.
11. Harris WS (2008) The omega-3 index as a risk factor for coronary heart disease. Am J Clin Nutr 87, 1997-2002.
12. Domingo JL, Bocio A, Falcó G, et al. (2007) Benefits and risk of fish consumption: Part I. A quantitative analysis of the intake of omega-3 fatty acids and chemical contaminants. Toxicology 230, 219-226.
13. Mozaffarian D & Rimm EB (2006) Fish intake, contaminants, and human health: Evaluating the risks and the benefits. JAMA 296, 1885-1899.
14. Galli C & Risé P (2009) Fish consumption, omega 3 fatty acids and cardiovascular disease. The science and the clinical trials. Nutr Health 20, 11-20.
15. von Schacky C (2008) Omega-3 fatty acids pro-arrhythmic, anti-arrhytmic or both? Curr Op Nutr Metab Care 11, 94-99.
16. Itomura M, Fujioka S, Hamazaki K, et al. (2008) Factors influencing EPA + DHA levels in red blood cells in Japan. In Vivo 22, 131-135.
17. Sands SA, Reid KJ, Windsor SL, et al. (2005) The impact of age, body mass index, and fish intake on the EPA and DHA content of human erythrocytes. Lipids 40, 343-347.
18. von Schacky C & Harris WS (2007) Cardiovascular benefits of omega-3 fatty acids. Cardiovasc Res 73, 310-315.
19. Rzehak P, Heinrich J, Klopp N, et al. (2009) Evidence for an association between genetic variants of the fatty acid desaturase 1 fatty acid desaturase 2 (FADS1 FADS2) gene cluster and the fatty acid composition of erythrocyte membranes. Br J Nutr 101, 20-26.
20. Xie L & Innis SM (2008) Genetic variants of the FADS1 FADS2 gene cluster are associated with altered (n-6) and (n-3) essential fatty acids in plasma and erythrocyte phospholipids in women during pregnancy and in breast milk during lactation. J Nutr 138, 2222-2228.
21. Plourde M & Cunnane SC (2007) Extremely limited synthesis of long chain polyunsaturates in adults: Implications for their dietary essentiality and use as supplements. Appl Physiol Nutr Metab 32, 619-634.
22. von Schacky C (2007) Omega-3 Fettsäuren in der Kardiologie (Omega-3 fatty acids in cardiology). MMW-Fortschr Med Originalien III 149, 97-101.
23. Woodward M, Oliphant J, Lowe G, et al. (2003) Contribution of contemporaneous risk factors to social inequality in coronary heart disease and all causes mortality. Prev Med 36, 561-568.
24. Laaksonen M, Talala K, Martelin T, et al. (2008) Health behaviours as explanations for educational level differences in cardiovascular and all-cause mortality: A follow-up of 60 000 men and women over 23 years. Eur J Public Health 18, 38-43.
25. Cohen BE, Garg SK, Ali S, et al. (2008) Red blood cell docosahexaenoic acid and eicosapentaenoic acid concentrations are positively associated with socioeconomic status in patients with established coronary artery disease: Data from the Heart and Soul Study. J Nutr 138, 1135-1140.
26. Harris WS, Pottala JV, Sands SA, et al. (2007) Comparison of the effects of fish and fish-oil capsules on the n 3 fatty acid content of blood cells and plasma phospholipids. Am J Clin Nutr 86, 1621-1625.
27. Harris WS (2007) International recommendations for consumption of long-chain omega-3 fatty acids. J Cardiovasc Med (Hagerstown) 8, Suppl. 1, S50-S52.
28. Harris WS, Kris-Etherton PM & Harris KA (2008) Intakes of long-chain omega-3 fatty acid associated with reduced risk for death from coronary heart disease in healthy adults. Curr Atheroscler Rep 10, 503-509.
29. von Schacky C (2009) Use of red cell fatty acid profiles as biomarkers in cardiac disease. Biomark Med 3, 25-32.
30. Block RC, Harris WS, Reid KJ, et al. (2008) EPA and DHA in blood cell membranes from acute coronary syndrome patients and controls. Atherosclerosis 197, 821-828.
31. von Schacky C & Weber PC (1985) Metabolism and effects on platelet function of the purified eicosapentaenoic and docosahexaenoic acids in humans. J Clin Invest 76, 2446-2450.
32. von Schacky C, Fahrer C & Fischer S (1990) Catabolism of leukotriene B5 in humans. J Lipid Res 31, 1831-1838.
33. Kaminski WE, Jendraschak E, Kiefl R, et al. (1993) Dietary omega-3 fatty acids lower levels of PDGF mRNA in human monocular cells. Blood 81, 1871-1879.
34. Perino A, Cabras S, Obinu D, et al. (2009) Lactose intolerance: A non-allergic disorder often managed by allergologists. Eur Ann Allergy Clin Immunol 41, 3-16.
35. Ikeda I, Sasaki E, Yasunami H, et al. (1995) Digestion and lymphatic transport of eicosapentaenoic and docosahexaenoic acids given in the form of triacylglycerol, free acid and ethyl ester in rats. Biochim Biophys Acta 1259, 297-304.
36. Nelson GJ & Ackman RG (1988) Absorption and transport of fat in mammals with emphasis on n-3 polyunsaturated fatty acids. Lipids 23, 1005-1014.
37. Block RC, Harris WS & Pottala JV (2008) Determinants of blood cell omega-3 fatty acid content. Open Biomark J 1, 1-6.
38. Food and Drug Administration (1997) Substances affirmed as generally recognized as safe: Menhaden oil. Federal Register Environmental Documents, 30751-30757.
39. Yokoyama M, Origasa H, Matsuzaki M, et al. (2007) Japan EPA lipid intervention study (JELIS) investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised openlabel, blinded endpoint analysis. Lancet 369, 1090-1098.